Compare Stocks: DMRA, EWTX, DNTH, and TNGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMRA Damora Therapeutics, Inc. Common Stock	$21.81 +2.6%	$24.30	$4.95 ▼ $38.33	$1.35B	1.43	429,520 shs	35,113 shs
DNTH Dianthus Therapeutics	$79.99 +0.8%	$95.29	$32.28 ▼ $117.88	$4.38B	1.35	931,624 shs	265,125 shs
EWTX Edgewise Therapeutics	$40.03 +2.2%	$41.74	$15.66 ▼ $48.51	$4.32B	0.35	1.25 million shs	118,737 shs
TNGX Tango Therapeutics	$22.32 +0.6%	$23.85	$7.37 ▼ $34.39	$3.76B	1.17	3.49 million shs	891,075 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMRA Damora Therapeutics, Inc. Common Stock	+0.81%	+10.33%	+2.90%	-27.74%	+152.19%
DNTH Dianthus Therapeutics	+3.32%	+6.43%	-10.41%	-21.93%	+140.98%
EWTX Edgewise Therapeutics	-0.36%	+3.30%	-0.43%	-2.92%	+158.04%
TNGX Tango Therapeutics	-4.93%	-5.69%	-10.96%	-16.74%	+196.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMRA Damora Therapeutics, Inc. Common Stock	$21.81 +2.6%	$24.30	$4.95 ▼ $38.33	$1.35B	1.43	429,520 shs	35,113 shs
DNTH Dianthus Therapeutics	$79.99 +0.8%	$95.29	$32.28 ▼ $117.88	$4.38B	1.35	931,624 shs	265,125 shs
EWTX Edgewise Therapeutics	$40.03 +2.2%	$41.74	$15.66 ▼ $48.51	$4.32B	0.35	1.25 million shs	118,737 shs
TNGX Tango Therapeutics	$22.32 +0.6%	$23.85	$7.37 ▼ $34.39	$3.76B	1.17	3.49 million shs	891,075 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMRA Damora Therapeutics, Inc. Common Stock	+0.81%	+10.33%	+2.90%	-27.74%	+152.19%
DNTH Dianthus Therapeutics	+3.32%	+6.43%	-10.41%	-21.93%	+140.98%
EWTX Edgewise Therapeutics	-0.36%	+3.30%	-0.43%	-2.92%	+158.04%
TNGX Tango Therapeutics	-4.93%	-5.69%	-10.96%	-16.74%	+196.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DMRA Damora Therapeutics, Inc. Common Stock	3.00	Buy	$46.50	113.20% Upside
DNTH Dianthus Therapeutics	2.94	Moderate Buy	$128.54	60.69% Upside
EWTX Edgewise Therapeutics	2.83	Moderate Buy	$51.33	28.23% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$44.62	99.86% Upside

Current Analyst Ratings Breakdown

Latest DMRA, EWTX, DNTH, and TNGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/27/2026	DNTH Dianthus Therapeutics	Roth Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$113.00
10/23/2026	TNGX Tango Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$55.00
10/16/2026	TNGX Tango Therapeutics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/16/2026	EWTX Edgewise Therapeutics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/15/2026	DNTH Dianthus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	EWTX Edgewise Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$158.00
10/14/2026	EWTX Edgewise Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/29/2026	DMRA Damora Therapeutics, Inc. Common Stock	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$40.00
9/25/2026	DMRA Damora Therapeutics, Inc. Common Stock	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$40.00 ➝ $60.00
9/21/2026	EWTX Edgewise Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$45.00 ➝ $57.00

(Data available from 10/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	($110.11) per share	N/A
DNTH Dianthus Therapeutics	$1.90M	2,302.15	N/A	N/A	$11.41 per share	7.01
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.93 per share	N/A
TNGX Tango Therapeutics	$62.38M	60.34	N/A	N/A	$2.57 per share	8.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DMRA Damora Therapeutics, Inc. Common Stock	-$209.84M	-$3.37	N/A	N/A	N/A	N/A	-176.39%	-77.86%	N/A
DNTH Dianthus Therapeutics	-$162.34M	-$4.15	N/A	N/A	N/A	-10,096.95%	-22.53%	-21.55%	11/5/2026 (Estimated)
EWTX Edgewise Therapeutics	-$167.79M	-$1.85	N/A	N/A	N/A	N/A	-39.01%	-36.96%	11/5/2026 (Estimated)
TNGX Tango Therapeutics	-$101.59M	-$0.85	N/A	N/A	N/A	N/A	-25.75%	-23.36%	11/3/2026 (Estimated)

Latest DMRA, EWTX, DNTH, and TNGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	DNTH Dianthus Therapeutics	-$0.9445	N/A	N/A	N/A	$0.44 million	N/A
11/5/2026	Q3 2026	EWTX Edgewise Therapeutics	-$0.5320	N/A	N/A	N/A	$119.23 million	N/A
11/3/2026	Q3 2026	TNGX Tango Therapeutics	-$0.3530	N/A	N/A	N/A	$3.28 million	N/A
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A
8/10/2026	Q2 2026	DMRA Damora Therapeutics, Inc. Common Stock	-$0.4470	-$0.39	+$0.0570	-$0.39	N/A	N/A
8/6/2026	Q2 2026	EWTX Edgewise Therapeutics	-$0.4677	-$0.53	-$0.0623	-$0.53	N/A	N/A
8/4/2026	Q2 2026	DNTH Dianthus Therapeutics	-$0.8463	-$0.90	-$0.0537	-$0.90	$0.30 million	$0.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DMRA Damora Therapeutics, Inc. Common Stock	N/A	19.73	19.73
DNTH Dianthus Therapeutics	N/A	26.10	26.10
EWTX Edgewise Therapeutics	N/A	16.24	16.24
TNGX Tango Therapeutics	N/A	50.82	50.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DMRA Damora Therapeutics, Inc. Common Stock	14.20%
DNTH Dianthus Therapeutics	47.53%
EWTX Edgewise Therapeutics	N/A
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
DMRA Damora Therapeutics, Inc. Common Stock	0.40%
DNTH Dianthus Therapeutics	3.02%
EWTX Edgewise Therapeutics	21.30%
TNGX Tango Therapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DMRA Damora Therapeutics, Inc. Common Stock	40	61.74 million	61.49 million	No Data
DNTH Dianthus Therapeutics	92	54.80 million	53.14 million	Optionable
EWTX Edgewise Therapeutics	127	108.60 million	85.47 million	Optionable
TNGX Tango Therapeutics	137	168.61 million	157.65 million	Optionable

DMRA, EWTX, DNTH, and TNGX Headlines

Recent News About These Companies

Tango Therapeutics (TNGX) Expected to Post Earnings on Tuesday

October 27 at 6:40 AM | marketbeat.com

TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data

October 26 at 12:46 PM | zacks.com

Tango shares fall nearly 18% as pancreatic cancer response rate slips from June high

October 26 at 9:48 AM | thepharmaletter.comT

Stock Traders Purchase Large Volume of Call Options on Tango Therapeutics (NASDAQ:TNGX)

October 25 at 1:21 AM | americanbankingnews.com

Tango Therapeutics stock falls despite positive cancer trial data

October 23, 2026 | uk.finance.yahoo.com

Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript

October 23, 2026 | seekingalpha.com

Tango Therapeutics Inc. (TNGX) PT Raised to $55 at Stifel

October 23, 2026 | streetinsider.com

Tango Therapeutics, Inc. Reports Updated Results From Phase 1/2 Clinical Trial Of Vopimetostat In Combination With RAS(ON) Inhibitors

October 23, 2026 | marketscreener.comM

Tango Therapeutics Sinks 13% on Pancreatic Cancer Data It Says “Surpass Any Published PDAC Datasets”

October 23, 2026 | finance.yahoo.com

Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate

October 23, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Shares Gap Down - Here's What Happened

October 23, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Stock Sees Unusually High Call Option Buying

October 23, 2026 | marketbeat.com

Tango Therapeutics Maps 2027 Phase 3 Trial After Promising Cancer Data;Stock Down In Pre-Market

October 23, 2026 | rttnews.com

Can Tango Therapeutics (NASDAQ:TNGX) Redefine Cancer Care?

October 23, 2026 | kalkinemedia.comK

Tango Therapeutics Reports 82% Response Rate in Pancreatic Cancer Trial

October 23, 2026 | finance.yahoo.com

Tango Therapeutics Reports 82% Objective Response Rate for Vopimetostat Plus Daraxonrasib in Previously Treated Pancreatic Cancer; Plans Phase 3 Study in 2027

October 23, 2026 | quiverquant.comQ

Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug

October 23, 2026 | investors.com

Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

October 23, 2026 | globenewswire.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock Rated "Moderate Buy" by Sell-Side Brokerages

October 22, 2026 | americanbankingnews.com

Tango Therapeutics (TNGX) Stock Looks Fully Valued After A 252% Run

October 21, 2026 | finance.yahoo.com

Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In?

October 20, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA, EWTX, DNTH, and TNGX Company Descriptions

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

$21.81 +0.55 (+2.59%)

As of 11:39 AM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Dianthus Therapeutics NASDAQ:DNTH

$79.99 +0.66 (+0.83%)

As of 11:58 AM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Edgewise Therapeutics NASDAQ:EWTX

$40.03 +0.86 (+2.20%)

As of 11:58 AM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Tango Therapeutics NASDAQ:TNGX

$22.32 +0.13 (+0.60%)

As of 11:58 AM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DMRA, EWTX, DNTH, and TNGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DMRA, EWTX, DNTH, and TNGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DMRA, EWTX, DNTH, and TNGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA, EWTX, DNTH, and TNGX Company Descriptions

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Dianthus Therapeutics NASDAQ:DNTH

Edgewise Therapeutics NASDAQ:EWTX

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DMRA, EWTX, DNTH, and TNGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DMRA, EWTX, DNTH, and TNGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DMRA, EWTX, DNTH, and TNGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA, EWTX, DNTH, and TNGX Company Descriptions

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Dianthus Therapeutics NASDAQ:DNTH

Edgewise Therapeutics NASDAQ:EWTX

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools